Study guide
10.2 Peptic Ulcer Disease, Helicobacter pylori & Zollinger-Ellison Syndrome
MRCP UK
Track your progress as you read
Finished sections get a check mark.
1 MRCP(UK) Part 1: Exam Overview, Blueprint & Strategy
1.1 Part 1 Format, Delivery and Fees 1.2 The Official Blueprint and Mark Allocation 1.3 Scaled Scoring, Attempt Limits and Best-of-Five Technique
2 Clinical Sciences: Cellular, Genetic & Molecular Medicine
2.1 Organelles, Cytoskeleton & Membrane Transport 2.2 Cell Cycle Control, Apoptosis & Cell Signalling 2.3 Mendelian & Non-Mendelian Inheritance 2.4 Trinucleotide Repeat Disorders & Chromosomal Abnormalities 2.5 Purine, Pyrimidine Metabolism & the Porphyrias 2.6 Glycogen, Lipid Storage & Amino Acid Disorders
3 Clinical Sciences: Anatomy, Physiology & Immunology
3.1 Clinical & Cross-Sectional Anatomy 3.2 Systemic Clinical Physiology & Homeostasis 3.3 Clinical Immunology & Hypersensitivity Reactions
4 Clinical Sciences: Statistics, Epidemiology & Trial Design
4.1 Study Designs & Evidence Hierarchy 4.2 Diagnostic Testing, Screening & Predictive Values 4.3 Statistical Analysis & Risk Quantification
5 Clinical Pharmacology, Therapeutics & Toxicology
5.1 Pharmacokinetics & Pharmacodynamics 5.2 Cytochrome P450 Systems & High-Risk Drug Interactions 5.3 Adverse Drug Reactions & Therapeutic Drug Monitoring 5.4 Paracetamol & Salicylate Poisoning 5.5 Toxidromes, Antidotes, Carbon Monoxide & Toxic Alcohols
6 Cardiology: Coronary Artery Disease & Heart Failure
6.1 Acute Coronary Syndromes & Myocardial Infarction 6.2 Heart Failure & Cardiomyopathies 6.3 Cardiac Assessment & ECG Interpretation
7 Cardiology: Arrhythmias, Valvular & Pericardial Disease
7.1 Atrial Fibrillation, Narrow & Broad Complex Tachycardias 7.2 Bradyarrhythmias, Conduction Block & Antiarrhythmic Drugs 7.3 Valvular Heart Disease & Murmur Interpretation 7.4 Infective Endocarditis 7.5 Pericardial & Acute Aortic Diseases
8 Respiratory Medicine: Airway & Parenchymal Lung Disease
8.1 Asthma: Diagnosis, Chronic Management & Acute Attacks 8.2 COPD: GOLD Staging, Stable Management, Exacerbations & NIV 8.3 Interstitial Lung Disease & Sarcoidosis 8.4 Respiratory Infections & Bronchiectasis
9 Respiratory Medicine: Vascular, Pleural & Sleep Disorders
9.1 Venous Thromboembolism & Pulmonary Embolism 9.2 Pleural Effusion & Pneumothorax 9.3 Respiratory Failure & Sleep-Disordered Breathing
10 Gastroenterology: Luminal Gastrointestinal Disease
10.1 GORD, Barrett's Oesophagus & Oesophageal Motility Disorders 10.2 Peptic Ulcer Disease, Helicobacter pylori & Zollinger-Ellison Syndrome 10.3 Crohn's Disease, Ulcerative Colitis & Extraintestinal Manifestations 10.4 IBD Medical Therapy, Coeliac Disease & Malabsorption 10.5 Acute Upper Gastrointestinal Bleeding: Risk Scores, Ulcer & Variceal Haemorrhage 10.6 Lower Gastrointestinal Disorders & Colonic Neoplasia
11 Gastroenterology: Liver, Biliary & Pancreatic Disease
11.1 Viral Hepatitis A to E 11.2 Autoimmune Hepatitis & Metabolic Liver Disease 11.3 Cirrhosis & Complications of Portal Hypertension 11.4 Cholestatic Liver Disease: PBC and PSC 11.5 Gallstone Disease, Biliary Sepsis & Pancreatitis
12 Endocrinology & Diabetes: Diabetes & Thyroid
12.1 Diabetes: Diagnostic Thresholds, Classification & Pathophysiology 12.2 NICE-Directed Type 2 Therapy & Microvascular Complications 12.3 Acute Diabetic Emergencies (DKA & HHS) 12.4 Thyrotoxicosis, Thyroiditis & Management of Hyperthyroidism 12.5 Hypothyroidism, Subclinical Disease & Thyroid Nodules
13 Endocrinology & Diabetes: Adrenal, Pituitary & Calcium
13.1 Hypopituitarism, Pituitary Apoplexy & Hyperprolactinaemia 13.2 Acromegaly, Diabetes Insipidus & SIADH 13.3 Cushing's Syndrome: Aetiology, Screening & Localisation 13.4 Adrenal Insufficiency & Endocrine Hypertension 13.5 Calcium Regulation & Hypercalcaemia 13.6 Hypocalcaemia & Metabolic Bone Disease
14 Renal Medicine: AKI, Glomerular & Tubulointerstitial Disease
14.1 Acute Kidney Injury & Chronic Kidney Disease 14.2 Nephrotic and Nephritic Syndromes & Primary Glomerular Disease 14.3 Rapidly Progressive Glomerulonephritis 14.4 Tubulointerstitial & Inherited Renal Diseases
15 Renal Medicine: Fluid, Electrolytes & Acid-Base Balance
15.1 Sodium & Water Disorders 15.2 Potassium, Magnesium & Phosphate Disorders 15.3 Acid-Base Disorders & Blood Gas Analysis
16 Neurology: Cerebrovascular, Headache & Demyelinating Disease
16.1 Stroke Classification, Brainstem Syndromes & Hyperacute Reperfusion 16.2 Secondary Prevention, TIA, Carotid Surgery & Intracranial Haemorrhage 16.3 Headache Disorders & Cranial Neuralgias 16.4 Multiple Sclerosis & Central Demyelinating Diseases
17 Neurology: Epilepsy, Movement Disorders & Neuromuscular Disease
17.1 Epilepsy & Acute Seizures 17.2 Movement Disorders & Cognitive Impairment 17.3 Neuromuscular Junction & Peripheral Nerve Disorders
18 Rheumatology: Inflammatory Arthritis & Connective Tissue Disease
18.1 Rheumatoid Arthritis: Pathophysiology, Clinical Features & Diagnosis 18.2 DMARDs, Biologics & Their Toxicities 18.3 Seronegative Spondyloarthropathies 18.4 Systemic Lupus Erythematosus & Drug-Induced Lupus 18.5 Systemic Sclerosis & Scleroderma Renal Crisis 18.6 Sjogren's Syndrome & Inflammatory Myopathies
19 Rheumatology: Systemic Vasculitis & Crystal Arthropathy
19.1 Vasculitis Classification, Large and Medium Vessel Disease 19.2 ANCA-Associated and Immune Complex Small Vessel Vasculitis 19.3 Gout & Calcium Pyrophosphate Deposition Disease
20 Infectious Diseases & Tropical Medicine
20.1 Sepsis-3 Definitions & the Sepsis Six 20.2 Bacterial Meningitis, CSF Interpretation & Toxic Shock Syndrome 20.3 Tuberculosis: Pathogenesis & Clinical Manifestations 20.4 Tuberculosis: Diagnosis & Anti-Tuberculous Therapy 20.5 HIV Infection & Opportunistic Diseases 20.6 Malaria: Species, Life Cycle & Severe Disease 20.7 Enteric Fever, Arboviral Infection & Tissue Parasites
21 Haematology: Anaemias & Red Cell Disorders
21.1 MCV-Based Diagnostic Approach to Anaemia 21.2 Haemolytic and Autoimmune Haemolytic Anaemias 21.3 Membranopathies, Enzymopathies, PNH & Sickle Cell Disease
22 Haematology: Malignancy, Coagulation & Transfusion Medicine
22.1 Acute Leukaemias 22.2 Chronic Leukaemias & Myeloproliferative Neoplasms 22.3 Lymphomas & Plasma Cell Dyscrasias 22.4 Coagulation Cascade & Inherited Bleeding Disorders 22.5 Thrombocytopenia & Thrombotic Microangiopathies 22.6 Transfusion Products & Acute Transfusion Reactions
23 Psychiatry in General Medicine
23.1 Mood & Psychotic Disorders in Medical Patients 23.2 Psychiatric Emergencies & Substance Misuse 23.3 Mental Capacity & UK Mental Health Law
24 Geriatric Medicine
24.1 Comprehensive Geriatric Assessment, Frailty, Delirium & Falls 24.2 Polypharmacy, Deprescribing & Pressure Ulcers
25 Dermatology
25.1 Inflammatory Skin Disease, Immunobullous Disorders & Severe Drug Eruptions 25.2 Cutaneous Malignancy
26 Oncology & Palliative Medicine
26.1 Neutropenic Sepsis, Spinal Cord Compression & SVC Obstruction 26.2 Hypercalcaemia of Malignancy & Tumour Lysis Syndrome 26.3 Palliative Care & End-of-Life Symptom Control
27 Medical Ophthalmology
27.1 The Acute Red Eye & Sudden Painless Visual Loss 27.2 Retinopathy in Systemic Disease
10.2 Peptic Ulcer Disease, Helicobacter pylori & Zollinger-Ellison Syndrome
Key Takeaways Explain This Topic AI
Proton pump inhibitors must be stopped for two weeks before urea breath testing or stool antigen testing for Helicobacter pylori to avoid false negatives.
Zollinger-Ellison syndrome is confirmed by a markedly raised fasting gastrin with gastric pH below 2, and about 25% of cases occur within MEN1.
Standard UK first-line Helicobacter pylori eradication is a proton pump inhibitor with amoxicillin plus either clarithromycin or metronidazole for seven days.
Last updated: September 2026
- 3. Peptic Ulcer Disease (PUD) & Helicobacter pylori
- Gastric vs Duodenal Ulcers
Peptic ulcer disease arises when aggressive luminal factors (hydrochloric acid, pepsin, NSAIDs, H. pylori ) overwhelm endogenous gastroduodenal mucosal protective mechanisms (mucus layer, bicarbonate secretion, prostaglandins, tight intercellular junctions, mucosal blood flow).
- Feature Duodenal Ulcer (DU) Gastric Ulcer (GU)
- Relative Frequency ~80–85% of peptic ulcers ~15–20% of peptic ulcers
- Peak Age 30–55 years 55–70 years
- H. pylori Association ~90–95% ~70–80%
Pathophysiological Driver Acid and pepsin hypersecretion; uninhibited gastrin drive Mucosal barrier breakdown, mucosal atrophy, NSAIDs
Pain Timing & Food Relationship Occurs 2–3 hours after meals or at night (relieved by food and antacids) Provoked or exacerbated by food ; occurs immediately postprandially
Nutritional Impact Normal or weight gain (frequent eating relieves pain) Anorexia and weight loss (food avoidance due to pain)
Malignant Transformation Exceedingly rare (<0.1%) ; almost universally benign ~3–5% harbor gastric adenocarcinoma
Endoscopic Follow-up Not routinely indicated once healed clinically Mandatory repeat endoscopy at 6–8 weeks with re-biopsy to prove healing
Helicobacter pylori Pathogenesis
Helicobacter pylori is a microaerophilic, flagellated, spiral Gram-negative bacillus adapted to colonize the human gastric mucosa:
Urease Activity: Synthesizes large amounts of the enzyme urease, which hydrolyses luminal urea into carbon dioxide and ammonia (NH3) . Ammonia buffers ambient gastric hydrochloric acid, raising peri-bacterial pH and permitting survival within the acidic mucosal mucus layer.
Virulence Cytotoxins:
CagA (Cytotoxin-Associated Gene A): Translocated into gastric epithelial cells via a Type IV secretion system, inducing cellular cytoskeletal rearrangements, nuclear factor-kappa B (NF-kB) activation, and massive secretion of interleukin-8 (IL-8) , provoking intense neutrophilic infiltration.
VacA (Vacuolating Cytotoxin A): Inserts into host cell membranes, forming pores that induce endosomal vacuolation, mitochondrial dysfunction, and epithelial apoptosis.
Phenotypic Patterns of Infection:
Antral-Predominant Gastritis: Localized inflammation in the gastric antrum leads to targeted destruction of somatostatin-producing D-cells . Loss of somatostatin's inhibitory tonic control causes uninhibited release of gastrin from G-cells . Hypergastrinaemia stimulates corpus parietal cells, resulting in marked gastric acid hypersecretion , delivering excess acid to the duodenal bulb, inducing gastric metaplasia, and driving duodenal ulceration .
Corpus-Predominant Gastritis / Pangastritis: Inflammation involves the acid-secreting corpus, leading to progressive destruction of parietal cells, loss of intrinsic factor, profound hypochlorhydria , and multifocal atrophic gastritis . This drives intestinal metaplasia, dysplasia, and significantly elevates the risk of gastric adenocarcinoma .
Gastric MALT Lymphoma: Chronic H. pylori antigen-driven B-cell stimulation within mucosa-associated lymphoid tissue induces clonal low-grade B-cell marginal zone lymphomas. Early-stage (Ann Arbor Stage IE) MALT lymphomas achieve complete histological regression in >75% of cases solely following successful H. pylori eradication .
Diagnostic Testing for Helicobacter pylori
Diagnostic modalities are categorized into non-invasive and invasive tests. Both urea-dependent non-invasive tests require strict patient preparation:
Prerequisite Rules: Patients must stop proton pump inhibitors (PPIs) for at least 2 weeks and stop antibiotics and bismuth compounds for at least 4 weeks before testing. Failure to do so suppresses bacterial load and urease activity, generating false-negative results .
Diagnostic Test Modality & Mechanism Key Indications & Caveats
13C-Urea Breath Test (UBT) Non-invasive. Patient ingests 13C-labelled urea; bacterial urease cleaves urea to produce 13CO2, measured in exhaled breath via mass spectrometry. Sensitivity and specificity >95%. Preferred test for initial diagnosis and test-of-cure (performed >=4 weeks post-treatment).
Stool Antigen Test (SAT) Non-invasive. Monoclonal enzyme-linked immunoassay (ELISA) detects active H. pylori bacterial antigens in stool. Equal accuracy to UBT (>95% sensitivity). Highly cost-effective; suitable for initial diagnosis and proof of eradication.
Serum Serology (IgG) Non-invasive. Enzyme immunoassay measures circulating anti- H. pylori IgG antibodies. Indicates past exposure; remains positive for months to years after successful cure. Cannot differentiate active from resolved infection ; useless for test-of-cure.
Rapid Urease Test (CLOtest) Invasive. Antral mucosal biopsy placed in urea-containing medium with phenol red indicator; ammonia production shifts pH, turning yellow medium pink. Highly accurate (>90%) during index endoscopy. Subject to false negatives if recent PPI or antibiotic use.
Histology & Culture Invasive. Warthin-Starry silver or Giemsa staining of endoscopic biopsies. Culture permits antibiotic susceptibility testing. Gold standard for refractory infections requiring tailored salvage antimicrobial regimens.
Eradication Regimens (NICE & BSG Guidelines)
First-Line Standard Triple Therapy (Low Clarithromycin Resistance Areas):
- Twice-daily PPI (e.g., omeprazole 20 mg BD or lansoprazole 30 mg BD) +
- Amoxicillin 1 g BD +
Clarithromycin 500 mg BD (or Metronidazole 400 mg BD if penicillin-allergic) for 7 to 14 days .
Bismuth Quadruple Therapy (High Clarithromycin Resistance Areas or Previous Macrolide Exposure):
- Twice-daily PPI +
- Bismuth subsalicylate / subcitrate (120–240 mg QDS) +
- Metronidazole 400 mg TDS +
Tetracycline hydrochloride 500 mg QDS for 10 to 14 days .
Salvage / Second-Line Therapy: In patients failing first-line triple therapy, switch to bismuth quadruple therapy or a levofloxacin-containing triple regimen (PPI + Amoxicillin 1 g BD + Levofloxacin 500 mg OD). Always confirm eradication with 13C-UBT or stool antigen >=4 weeks after treatment in complicated PUD, MALToma, or persistent symptoms.
- 4. Zollinger-Ellison Syndrome (ZES)
- Pathophysiology & Clinical Features
Zollinger-Ellison syndrome is caused by a gastrinoma —a functional neuroendocrine tumour that hypersecretes the peptide hormone gastrin. Approximately 70–80% of gastrinomas arise within the anatomical boundaries of the "gastrinoma triangle" (defined by the junction of the cystic and common bile duct superiorly, the junction of the second and third parts of the duodenum inferiorly, and the neck and body of the pancreas medially). Up to 60% of gastrinomas are malignant, metastasizing predominantly to regional lymph nodes and the liver.
Multiple Endocrine Neoplasia Type 1 (MEN1): Approximately 20–25% of ZES cases occur in association with MEN1 , an autosomal dominant disorder caused by germline inactivating mutations in the MEN1 tumour suppressor gene on chromosome 11q13. MEN1 is defined by the triad of parathyroid hyperplasia/adenomas (95%, hypercalcaemia) , pituitary adenomas (prolactinoma, GH-secreting) , and pancreatic/duodenal neuroendocrine tumours (gastrinoma, insulinoma) . Gastrinomas in MEN1 are typically multifocal, duodenal, and diagnosed at an earlier age.
Clinical Presentation:
Severe, Recurrent, or Atypical Peptic Ulceration: Peptic ulcers occur in >90% of patients; classic red flags include ulcers refractory to standard PPI therapy, multiple synchronous ulcers, ulcers occurring in atypical anatomical locations (distal duodenum or jejunum), or ulcer perforation.
Severe Chronic Diarrhoea & Steatorrhoea: Present in ~50% of cases and can precede ulcer symptoms. Massive volumes of gastric acid delivered to the proximal small bowel overwhelm pancreatic bicarbonate reserves, acidifying the duodenal lumen (pH <3). This denatures pancreatic digestive enzymes (particularly pancreatic lipase) and precipitates conjugated bile acids, inducing fat malabsorption and osmotic/secretory diarrhoea.
Severe GORD and Oesophagitis: Acid hypersecretion provokes extensive erosive oesophagitis and peptic strictures.
Diagnostic Algorithm & Localization
Fasting Serum Gastrin (FSG): Initial screening test of choice. The patient must discontinue PPIs for at least 1–2 weeks (withholding acid suppression leads to physiological hypergastrinaemia in normal individuals). A fasting serum gastrin >1000 pg/mL (normal <100 pg/mL) accompanied by a gastric pH <=2.0 is virtually diagnostic of ZES.
Secretin Stimulation Test: Indicated when fasting serum gastrin is moderately elevated (150–1000 pg/mL) and gastric pH is <=2.0, to definitively differentiate a gastrinoma from other causes of hypergastrinaemia (such as antral G-cell hyperplasia, atrophic gastritis, or gastric outlet obstruction):
Mechanism: Intravenous administration of secretin (2 clinical units/kg). In healthy subjects or atrophic gastritis, secretin inhibits antral G-cells, causing gastrin levels to fall or remain unchanged. In gastrinomas, secretin binds directly to abnormal receptors on neoplastic gastrinoma cells, triggering a paradoxical, rapid surge in serum gastrin .
Positive Diagnostic Criterion: A rise in serum gastrin of >120 pg/mL (or >200 ng/L) above baseline drawn at 10 to 15 minutes confirms Zollinger-Ellison syndrome.
Tumour Localization:
68Ga-DOTATATE / DOTATOC PET-CT: Somatostatin receptor scintigraphy utilizing positron emission tomography; exhibits superior sensitivity (>90%) for identifying primary tumours and distant hepatic metastases.
Endoscopic Ultrasound (EUS): Outstanding sensitivity for small duodenal and pancreatic head lesions.
Management: High-dose oral PPI therapy (e.g., omeprazole 60–120 mg daily) to control acid hypersecretion; surgical exploratory laparotomy with curative lymphadenectomy and enucleation/resection in sporadic, non-metastatic gastrinomas. Patients with MEN1 require medical acid suppression and management of concurrent hyperparathyroidism.